2024-11-27 - Analysis Report
## Johnson & Johnson (JNJ) Stock Analysis Report

**1. Performance Comparison and Divergence:**

Johnson & Johnson (JNJ), a leading healthcare company producing medical devices, pharmaceuticals, and consumer health products, has significantly underperformed the S&P 500 (VOO) over the analyzed period.  While JNJ showed a cumulative return of 36.58%, VOO achieved 128.31%. This results in a substantial lag of -91.7%.  The relative divergence of 2.3% indicates that JNJ's performance is near the lower bound of its historical performance range relative to the S&P 500.  The provided CAGR data shows a generally declining trend in recent years, suggesting slowing growth.

**2. Recent Price Movement:**

* **Last Price:** $155.78 (Last market close: $154.2)
* **5-day Moving Average:** $154.51
* **20-day Moving Average:** $156.07
* **60-day Moving Average:** $160.98

The price is slightly below the 20-day moving average and significantly below the 60-day moving average, suggesting a possible short-term downward trend.  The difference between the last price and the last market close is minimal.

**3. Technical Indicators and Expected Return:**

* **RSI (41.86):**  Indicates the stock is approaching oversold territory, suggesting potential for a short-term rebound.
* **PPO (0.14):** A positive value suggests a bullish momentum, though relatively weak.
* **Relative Divergence (20-day):** -3.8% indicates a recent short-term decline in relative performance against the S&P 500.
* **Expected Return (2+ years):** 0.0%.  This suggests that, based on the provided data, long-term accumulation in JNJ is not expected to outperform the S&P 500 significantly.  Further analysis is required to validate this projection.  The fact that the $154.2 value (if assumed to be a significantly lower value than the Last Market value) doesn't suggest a dramatic price change.  However, the context is needed to understand the significance of this number in the short term.

**4. Recent Earnings and Outlook:**

JNJ's recent earnings show some volatility in EPS, with a significant drop in the October 2023 quarter, potentially due to seasonal factors or other market dynamics. The provided data lacks details such as earnings estimates to make a full assessment.  A more comprehensive analysis of future earnings estimates would be necessary to get a better view on profitability trends.

| Date       | EPS    | Revenue (B$) |
|------------|--------|-------------|
| 2024-10-23 | 1.12   | 22.47       |
| 2024-07-25 | 1.95   | 22.45       |
| 2024-05-01 | 1.35   | 21.38       |
| 2024-02-16 | 1.68   | 21.39       |
| 2023-10-27 | 10.32  | 21.35       |


**5. Financial Information:**

The revenue is relatively stable, but profitability metrics need to be scrutinized more deeply.  While profit margins consistently remain high (~69%), the ROE shows significant volatility quarter to quarter, indicating fluctuations in profitability and potentially suggesting operational challenges or changing investment strategies.  Further investigation into the 36.54% ROE in 2023-09-30 is necessary to understand the source of this anomaly.

**6. News and Recent Issues:**

* _Information missing._  Please provide recent news articles (from sources like Shacknews or FINBOLD) within the last 48 hours to facilitate a more complete analysis.  This section needs further details on recent market outlook, analyst opinions, and performance highlights.


**7. Overall Analysis:**

JNJ's performance has lagged behind the S&P 500. While technical indicators suggest potential for a short-term rebound, the long-term outlook remains uncertain.  The company's financial data shows inconsistencies that require further investigation to understand the underlying drivers.  The absence of recent news and detailed earnings expectations prevents a complete evaluation.  A more thorough analysis, including an examination of the October 2023 EPS drop and the 36.54% ROE outlier and incorporating recent news and analyst sentiment, is crucial before making any investment decision.


**8. Recommendations:**

Given the limited data and lack of recent news, a definitive recommendation cannot be made.  Further investigation into the financial statements, earnings estimates, and recent market news is recommended before forming an investment strategy.  Consider consulting with a financial advisor to discuss the risk-reward profile of investing in JNJ based on your individual circumstances.
